Xencor Inc
XNCR Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$25.18
KIRA · Stoqly’s AI analyst, in plain words
- Xencor Inc had $126M of revenue in fiscal 2025, up 13.7% on the year before. Over five years, revenue changed +0.5% a year on average.
- Its operating margin was −141.4%, up 20.1 pts: of every 100 in sales, about −141 is left after running the business.
- Xencor Inc lost $91.9M in fiscal 2025.
- Free cash flow was −$138M in fiscal 2025, −110.1% of revenue.
- Xencor Inc owes $65.7M more than it holds in cash.
Market cap
$1.9B
P/E
—
Revenue
$126M
Net income
−$91.9M
Free cash flow
−$138M
Operating margin
−141.4%
Xencor Inc in 30 seconds · fiscal 2025
Are sales growing?
+13.7%
Yes. Sales grew 13.7% last year.
Does it make a profit?
−73.2%
No. It lost money last year.
Does profit turn into cash?
−110.1%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Xencor Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 25, 2026
- Legal name
- Xencor Inc
- CIK
- 0001326732
Xencor Inc · XNCR
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $275M | $165M | $175M | $110M | $126M |
| Revenue growth | 124.2% | −40.2% | 6.1% | −36.7% | 13.7% |
| Net interest income | $0.8M | $4.8M | $19.3M | $31.9M | — |
| Operating margin | 15.9% | −50.1% | −75.8% | −161.5% | −141.4% |
| Net income | $82.6M | −$55.2M | −$133M | −$233M | −$91.9M |
| Net margin | 30.0% | −33.5% | −76.2% | −210.5% | −73.2% |
| Diluted EPS | $1.37 | −$0.93 | −$2.20 | −$3.58 | −$1.24 |
| Cash | |||||
| Cash from operations | −$16.9M | $24.5M | −$77.9M | −$202M | −$135M |
| Capital expenditure | $13.3M | $38.5M | $18.4M | $6.1M | $3.2M |
| Free cash flow | −$30.2M | −$14.0M | −$96.4M | −$208M | −$138M |
| FCF margin | −11.0% | −8.5% | −55.2% | −188.5% | −110.1% |
| Share count change | 5.7% | −1.4% | 1.4% | 7.5% | 14.1% |
| Debt and strength | |||||
| Cash and short-term investments | $143M | $53.9M | $53.8M | $40.9M | $54.1M |
| Debt incl. finance leases | — | $0.0M | $189M | $164M | $120M |
| Shareholders' equity | $734M | $727M | $662M | $678M | $636M |
| Current ratio | 6.0x | 10.6x | 8.6x | 6.6x | 6.3x |
| Interest coverage | 3,366.7x | −6,344.1x | −21.4x | −4.9x | −5.6x |
| Returns and quality | |||||
| Return on capital | — | −9.7% | −13.1% | −17.6% | −20.0% |
| Return on equity | 12.7% | −7.6% | −19.2% | −34.7% | −14.0% |
| Return on tangible equity | 11.5% | −7.8% | −20.7% | −35.3% | −14.7% |
| Piotroski F-score | 4 | 4 | 1 | 2 | 3 |
| Altman Z'' | 9.4 | 9.2 | 3.6 | 2.3 | 2.2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$3.9M
9 insiders
Of sales under plans
10%
$0.4M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Xencor Inc · XNCR
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $25.18 a share, the company is worth $1.9B.
Source: SEC EDGAR XBRL filings (CIK 0001326732). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.